Trial Profile
A retrospective chart review assessing the role of antifibrotic therapy in subset (FVC < 50% predicted) of idiopathic pulmonary fibrosis patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Jul 2017
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary) ; Pirfenidone (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- 13 Jul 2017 New trial record
- 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society